Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Bought by Venturi Wealth Management LLC

Venturi Wealth Management LLC lifted its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 229.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,725 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,899 shares during the period. Venturi Wealth Management LLC’s holdings in Jazz Pharmaceuticals were worth $336,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. UMB Bank n.a. grew its stake in shares of Jazz Pharmaceuticals by 70.9% during the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock valued at $38,000 after buying an additional 129 shares during the period. Itau Unibanco Holding S.A. boosted its holdings in Jazz Pharmaceuticals by 63.2% in the third quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock valued at $49,000 after acquiring an additional 172 shares during the last quarter. GAMMA Investing LLC grew its position in Jazz Pharmaceuticals by 49.8% during the fourth quarter. GAMMA Investing LLC now owns 620 shares of the specialty pharmaceutical company’s stock valued at $76,000 after acquiring an additional 206 shares during the period. Versant Capital Management Inc increased its stake in Jazz Pharmaceuticals by 56.7% during the fourth quarter. Versant Capital Management Inc now owns 967 shares of the specialty pharmaceutical company’s stock worth $119,000 after acquiring an additional 350 shares during the last quarter. Finally, Signaturefd LLC raised its holdings in shares of Jazz Pharmaceuticals by 273.4% in the 3rd quarter. Signaturefd LLC now owns 1,516 shares of the specialty pharmaceutical company’s stock worth $169,000 after purchasing an additional 1,110 shares during the period. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Piper Sandler reiterated an “overweight” rating and set a $163.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Morgan Stanley raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $140.00 to $175.00 in a research report on Thursday, December 12th. HC Wainwright restated a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. TD Cowen decreased their price target on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $179.00 price objective on shares of Jazz Pharmaceuticals in a research report on Tuesday, December 10th. One analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $180.33.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the firm’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total transaction of $185,145.00. Following the completion of the transaction, the chief executive officer now directly owns 425,525 shares of the company’s stock, valued at $52,522,550.75. This trade represents a 0.35 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 5,053 shares of company stock valued at $617,442 over the last ninety days. Corporate insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $136.84 on Friday. The firm has a market cap of $8.27 billion, a price-to-earnings ratio of 19.27, a PEG ratio of 1.03 and a beta of 0.56. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The business’s 50 day moving average is $124.59 and its two-hundred day moving average is $117.82. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $138.27.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.